Every 8-K that REVIUM RECOVERY INC (RVRC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RVRC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVRC filings page.
Revium Rx. reported that Ms. Inna Martin has resigned, effective immediately, from her roles as Director, Chief Operating Officer, and President. The company cites differences in expectations between Ms. Martin and the company as the reason for her departure. She did not serve on any board committees at the time of resignation.
Under a Separation Agreement with subsidiary Revium Rx Ltd., Ms. Martin’s employment and consultancy will end on September 10, 2026. The exercise period for her vested stock options to purchase up to 2,440,000 shares of common stock has been extended until September 30, 2028, and her shares and options are subject to sale restrictions specified in the agreement.
Revium Rx. reported a leadership change in its finance function. On May 27, 2026, Chief Financial Officer Arie Gordashnikov resigned from the company and its subsidiaries, effective immediately. The company states that his resignation did not result from any disagreement regarding operations, policies, or practices.
On the same date, the Board appointed Igor Bluvstein as the new Chief Financial Officer of Revium Rx. and its subsidiaries, also effective immediately. Bluvstein brings more than 17 years of financial leadership experience across pharmaceutical, digital health, biotechnology, e-commerce, and petrochemical industries and is a Certified Public Accountant. In connection with his appointment, he will receive a monthly retainer of NIS17,000 plus VAT.
Revium Rx named Amir Avraham as permanent Chief Executive Officer, effective February 1, 2026, after serving in the role on an interim basis. His compensation includes a monthly salary of NIS 55,000, eligibility for an annual discretionary cash bonus, and a one-time $50,000 bonus tied to raising at least $5 million in new equity investments within 18 months.
Under the company’s Global Share Incentive Plan, he is to receive options for 1,300,000 common shares starting vesting on February 1, 2026, plus additional option grants of 300,000 shares each upon meeting $3,000,000 investment and M&A milestones. The company also appointed Shlomi Schwartzblat as a director and Chairman of the Board, with his term running until the 2026 annual stockholder meeting.